Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0385 · 1 trial · 1 indication
Measured in h \* nmol/L
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 G tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 B tablet orally in the 5-day treatment period (period 2). |
| Sequence 2 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 G tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 F tablet orally in the 5-day treatment period (period 2). |
| Sequence 3 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 F tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 B tablet orally in the 5-day treatment period (period 2). |
| Sequence 4 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 F tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 G tablet orally in the 5-day treatment period (period 2). |
| Sequence 5 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 B tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 G tablet orally in the 5-day treatment period (period 2). |
| Sequence 6 | EXPERIMENTAL | Participants will receive oral dose of NNC0385-0434 B tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 F tablet orally in the 5-day treatment period (period 2). |
| Name | Type | Description |
|---|---|---|
| NNC0385-0434 G | DRUG | Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2). |
| NNC0385-0434 F | DRUG | Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2). |
| NNC0385-0434 B | DRUG | Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2). |
Inclusion Criteria: * Male * Aged 18-64 years (both inclusive) at the time of signing informed consent * Body mass index between 20.0 and 32.0 kilogram per meter square (both inclusive) * Considered to be generally healthy based on the medical history, physical examination, and the results of vital...
NNC0385 is an investigational small molecule being developed for high cholesterol. It is currently in Phase 1 clinical development, studied in healthy volunteers and individuals with high cholesterol. The drug is being evaluated as a protein-based tablet formulation.
NNC0385 is being developed by Novo Nordisk A/S, a biopharmaceutical company traded on the stock exchange under the ticker NVO. The company is conducting clinical research on this investigational drug for the treatment of high cholesterol.
NNC0385 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a completed Phase 1 trial involving healthy volunteers and participants with high cholesterol.
NNC0385 has one completed clinical trial registered as NCT05333107, titled "A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II." This Phase 1 study enrolled 152 male participants aged 18 years and older in the United States.
NNC0385 is being studied as a protein-based tablet formulation. The clinical trial NCT05333107 specifically evaluates this oral formulation in healthy men. The drug is a small molecule, and the research focuses on its use for high cholesterol.